⌘K
Loading ticker…
Harvard Bioscience Inc · Healthcare · Measuring & Control Equipment
As of 2026-06-26, Harvard Bioscience Inc (HBIO) has a 3-month relative strength percentile of 70 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 54. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.5%, relative volume 0.34×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 70, Market Stance is mixed at 47, A/D rating B
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
HBIO is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $601K notional.
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $601K |
| VXFVanguard Extended Market ETF | 0.00% | $194K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HBIO Jan avg: -13.56% median: -18.36% win: 25% σ: 14.46% n: 4 2022-04-12 → 2026-05-29 | HBIO Feb avg: -8.69% median: -3.31% win: 25% σ: 30.55% n: 4 2022-04-12 → 2026-05-29 | HBIO Mar avg: -1.80% median: -11.36% win: 25% σ: 35.79% n: 4 2022-04-12 → 2026-05-29 | HBIO Apr avg: 0.86% median: -9.91% win: 40% σ: 31.59% n: 5 2022-04-12 → 2026-05-29 | HBIO May avg: -5.19% median: -7.84% win: 20% σ: 22.80% n: 5 2022-04-12 → 2026-05-29 | HBIO Jun avg: -4.62% median: -3.38% win: 0% σ: 3.96% n: 4 2022-04-12 → 2026-05-29 (current) | HBIO Jul avg: 1.59% median: 4.69% win: 75% σ: 11.82% n: 4 2022-04-12 → 2026-05-29 | HBIO Aug avg: -5.28% median: -7.58% win: 25% σ: 8.26% n: 4 2022-04-12 → 2026-05-29 | HBIO Sep avg: -10.73% median: -9.01% win: 0% σ: 8.61% n: 4 2022-04-12 → 2026-05-29 | HBIO Oct avg: 3.09% median: 3.59% win: 75% σ: 12.50% n: 4 2022-04-12 → 2026-05-29 | HBIO Nov avg: 8.28% median: -3.90% win: 25% σ: 26.05% n: 4 2022-04-12 → 2026-05-29 | HBIO Dec avg: 4.40% median: 2.06% win: 50% σ: 16.41% n: 4 2022-04-12 → 2026-05-29 |